Key takeaways
- Desmopressin acetate is FDA-approved for central diabetes insipidus, post-surgical polyuria, and primary nocturnal enuresis.
- It does not work for nephrogenic diabetes insipidus, where the kidneys cannot respond to it.
- More than 150 registered trials have studied desmopressin across a range of conditions.
- The most frequently reported adverse event in FDA safety reports is hyponatraemia, a low blood sodium level.
- It is marketed as Desmopressin Acetate and related tablet formulations.
What desmopressin is
Desmopressin is a synthetic peptide compound with a molecular weight of roughly 1,069 daltons (PubChem CID 5311065). It is formulated as an oral tablet and marketed under names including Desmopressin Acetate.
What desmopressin is approved for
Desmopressin acetate tablets are approved as antidiuretic replacement therapy for central diabetes insipidus, a condition where the body fails to properly regulate water balance. They are also approved for the temporary polyuria and polydipsia (excess urination and thirst) that can follow head trauma or surgery near the pituitary gland. A separate approved use is the management of primary nocturnal enuresis, commonly known as bedwetting. The label specifies that desmopressin does not work for nephrogenic diabetes insipidus, since that form involves a different physiological problem. Diagnosis for the diabetes insipidus indications typically relies on water deprivation testing, hypertonic saline infusion testing, or response to antidiuretic hormone, and ongoing response can be tracked through urine volume and osmolality.
What the evidence shows
Desmopressin has been studied in more than 150 registered clinical trials spanning multiple patient populations. A completed Phase 1 study assessed safety, tolerability, and pharmacokinetics in healthy subjects. A separate completed Phase 2 trial examined desmopressin in women with overactive bladder and nocturia, while another completed trial evaluated a melt formulation over 24 months of treatment for nocturia.
Reported side effects
Safety reports submitted to FDA's adverse event system reflect counts of reported reactions, not confirmed rates or proven causation. The most commonly reported reaction is hyponatraemia, with 354 reports, reflecting the drug's core antidiuretic action on sodium and water balance. Headache (267 reports) and gastrointestinal symptoms such as nausea (198) and vomiting (155) are also frequently reported, along with fatigue (172) and dizziness (137). A notable share of reports describe the drug as ineffective (258) or note off label use (141), which reflect patterns of use and outcome rather than direct physical side effects.